All In Biotech

Free tool

FAERS Monitor: Ongentys

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212489 or its brand name (Ongentys, Opicapone). Reports on generic versions are filed under their own applications.

Reports

2,446

Serious

1,874

77% of reports

Hospitalization

1,038

Death reported

250

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hallucination339
  • dyskinesia338
  • fall291
  • on and off phenomenon196
  • tremor163
  • death150
  • gait disturbance143
  • drug ineffective134
  • confusional state130
  • parkinson^s disease127
  • fatigue119
  • hallucination, visual116
  • dizziness112
  • mobility decreased112
  • anxiety111

Reports by year received

View as table
YearReports
20161
201721
201840
201961
2020177
2021567
2022277
2023243
2024258
2025358
2026443

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
on and off phenomenonSignal196314.7274.458,834
dyskinesiaSignal33872.165.323,478
hallucination, visualSignal11647.539.75,210
hallucinationSignal33938.835.212,451
mobility decreasedSignal11213.411.21,278
tremorSignal1638.57.31,071
fallSignal2917.56.81,665
confusional stateSignal1306.95.9657
gait disturbanceSignal1436.45.5656
anxietySignal1113.42.8184
dizziness1121.91.651
death1501.51.325
fatigue1191.31.19
drug ineffective1340.90.72
parkinson^s disease1270.00.01,084,453

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.